These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 2175059)

  • 1. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors.
    De Witte T; Schattenberg A; Van Dijk BA; Galama J; Olthuis H; Van der Meer JW; Kunst VA
    Transplantation; 1990 Dec; 50(6):964-8. PubMed ID: 2175059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation.
    Verdonck LF; de Graan-Hentzen YC; Dekker AW; Mudde GC; de Gast GC
    Bone Marrow Transplant; 1987 Jun; 2(1):73-8. PubMed ID: 2844337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant.
    Bowden RA; Slichter SJ; Sayers MH; Mori M; Cays MJ; Meyers JD
    Blood; 1991 Jul; 78(1):246-50. PubMed ID: 1648976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening.
    Miller WJ; McCullough J; Balfour HH; Haake RJ; Ramsay NK; Goldman A; Bowman R; Kersey J
    Bone Marrow Transplant; 1991 Mar; 7(3):227-34. PubMed ID: 1647829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
    Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
    Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters.
    van Prooijen HC; Visser JJ; van Oostendorp WR; de Gast GC; Verdonck LF
    Br J Haematol; 1994 May; 87(1):144-7. PubMed ID: 7947238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation.
    Mackinnon S; Burnett AK; Crawford RJ; Cameron S; Leask BG; Sommerville RG
    J Clin Pathol; 1988 Sep; 41(9):948-50. PubMed ID: 2848062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ; Ho WG; Bartoni K; Champlin RE
    Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
    Narvios AB; Lichtiger B
    Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis of cytomegalovirus infection.
    Bowden RA; Meyers JD
    Semin Hematol; 1990 Apr; 27(2 Suppl 1):17-21; discussion 28-9. PubMed ID: 2160127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
    Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
    Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors.
    Ljungman P; Larsson K; Kumlien G; Aschan J; Barkholt L; Gustafsson-Jernberg A; Lewensohn-Fuchs I; Ringdén O
    Scand J Infect Dis; 2002; 34(5):347-50. PubMed ID: 12069017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMV infections in bone marrow transplanted patients--evaluation of prophylaxis with Cytotect (CMV hyperimmuneglobulin).
    Zintl F; Färber I; Hermann J; Fuchs D; Prager J; Wutzler P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):557-64. PubMed ID: 2480308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s.
    Winston DJ; Gale RP
    Bone Marrow Transplant; 1991 Jul; 8(1):7-11. PubMed ID: 1655140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus infections after allogeneic bone marrow transplantation.
    Winston DJ; Ho WG; Champlin RE
    Rev Infect Dis; 1990; 12 Suppl 7():S776-92. PubMed ID: 2173107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation.
    Bowden RA; Sayers M; Flournoy N; Newton B; Banaji M; Thomas ED; Meyers JD
    N Engl J Med; 1986 Apr; 314(16):1006-10. PubMed ID: 3007984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections.
    Grob JP; Grundy JE; Prentice HG; Griffiths PD; Hoffbrand AV; Hughes MD; Tate T; Wimperis JZ; Brenner MK
    Lancet; 1987 Apr; 1(8536):774-6. PubMed ID: 2882184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experiences with transfusion of CMV tested blood preparations after bone marrow transplantation].
    Luboldt W; Henneberg-Quester KB; Schaefer UW; Beelen DW; Quabeck K; Thraenhart O
    Beitr Infusionsther; 1990; 26():190-3. PubMed ID: 1703827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.
    Bowden RA; Slichter SJ; Sayers M; Weisdorf D; Cays M; Schoch G; Banaji M; Haake R; Welk K; Fisher L; McCullough J; Miller W
    Blood; 1995 Nov; 86(9):3598-603. PubMed ID: 7579469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus-seronegative blood components for the prevention of primary cytomegalovirus infection after marrow transplantation. Considerations for blood banks.
    Bowden RA; Sayers M; Gleaves CA; Banaji M; Newton B; Meyers JD
    Transfusion; 1987; 27(6):478-81. PubMed ID: 2825381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.